Moraxella catarrhalis: From interactions with the host immune system to vaccine development

Future Microbiology

Volumn 7, Issue 9, 2012, Pages 1073-1100

  Su, Yu Ching ^a   Singh, Birendra ^a   Riesbeck, Kristian ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

adhesins; immune response; Moraxella catarrhalis; respiratory tract infection; vaccine

Indexed keywords

ADHESIN; ADJUVANT; AMOXICILLIN; AMPICILLIN; AZITHROMYCIN; BACTERIAL VACCINE; CELL ADHESION MOLECULE; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PATTERN RECOGNITION RECEPTOR; PENICILLIN G; PORIN; PROSTAGLANDIN E2; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VACCINE;

ANTIBIOTIC RESISTANCE; ANTIGEN PRESENTING CELL; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BACTERIOLYSIS; BACTERIUM ADHERENCE; CYTOKINE RELEASE; DENDRITIC CELL; GRANULOCYTE; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IMMUNE EVASION; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATION; MAST CELL; MORAXELLA CATARRHALIS; MORAXELLACEAE INFECTION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFECTION; REVIEW; SIGNAL TRANSDUCTION;

ADHESINS, BACTERIAL; BACTERIAL ADHESION; BACTERIAL VACCINES; HUMANS; IMMUNE EVASION; MORAXELLA (BRANHAMELLA) CATARRHALIS; MORAXELLACEAE INFECTIONS; NASOPHARYNX; RESPIRATORY TRACT INFECTIONS;

BACTERIA (MICROORGANISMS); MORAXELLA CATARRHALIS;

EID: 84866069938     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.80     Document Type: Review

References (220)

1. De Vries SP, Bootsma HJ, Hays JP, Hermans PW. Molecular aspects of Moraxella catarrhalis pathogenesis. Microbiol. Mol. Biol. Rev. 73(3), 389-406 (2009).
2. De Vries SP, Van Hijum SA, Schueler W et al. Genome analysis of Moraxella catarrhalis strain RH4, a human respiratory tract pathogen. J. Bacteriol. 192(14), 3574-3583 (2010).
3. Davie JJ, Earl J, De Vries SP et al. Comparative analysis and supragenome modeling of twelve Moraxella catarrhalis clinical isolates. BMC Genomics 12, 70 (2011).
4. Masaki H, Qin L, Zhou Z et al. A prospective study of intrafamilial transmission and antimicrobial susceptibility of Moraxella catarrhalis. Microbiol. Immunol. 55(9), 599-604 (2011).
5. Murphy TF, Bakaletz LO, Smeesters PR. Microbial interactions in the respiratory tract. Pediatr. Infect. Dis. J. 28(10 Suppl.), S121-S126 (2009).
6. Murphy TF, Brauer AL, Grant BJ, Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: Burden of disease and immune response. Am. J. Respir. Crit. Care Med. 172(2), 195-199 (2005).
7. Albertson TE, Louie S, Chan AL. The diagnosis and treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease and chronic bronchitis. J. Am. Geriatr. Soc. 58(3), 570-579 (2010).
8. Barbu C, Iordache M, Man MG. Inflammation in COPD: Pathogenesis, local and systemic effects. Rom. J. Morphol. Embryol. 52(1), 21-27 (2011).
9. Dunsmore SE. Treatment of COPD: A matrix perspective. Int. J. Chron. Obstruct. Pulmon. Dis. 3(1), 113-122 (2008).
10. Senior RM. Mechanisms of COPD: Conference summary. Chest 117(5 Suppl. 1), 320S-323S (2000).
11. Churg A, Zhou S, Wright JL. Series "matrix metalloproteinases in lung health and disease": Matrix metalloproteinases in COPD. Eur. Respir. J. 39(1), 197-209 (2012).
12. De Schutter I, De Wachter E, Crokaert F et al. Microbiology of bronchoalveolar lavage fluid in children with acute nonresponding or recurrent community-acquired pneumonia: Identification of nontypeable Haemophilus influenzae as a major pathogen. Clin. Infect. Dis. 52(12), 1437-1444 (2011).
13. Abdolrasouli A, Amin A, Baharsefat M, Roushan A, Hemmati Y. Moraxella catarrhalis associated with acute urethritis imitating gonorrhoea acquired by oral-genital contact. Int. J. STD AIDS 18(8), 579-580 (2007).
14. Sy MG, Robinson JL. Community-acquired Moraxella catarrhalis pneumonia in previously healthy children. Pediatr. Pulmonol. 45(7), 674-678 (2010).
15. Sano N, Matsunaga S, Akiyama T et al. Moraxella catarrhalis bacteraemia associated with prosthetic vascular graft infection. J. Med. Microbiol. 59(Pt 2), 245-250 (2010).
16. Murphy TF, Parameswaran GI. Moraxella catarrhalis, a human respiratory tract pathogen. Clin. Infect. Dis. 49(1), 124-131 (2009).
17. Levy F, Leman SC, Sarubbi FA, Walker ES. Nosocomial transmission clusters and risk factors in Moraxella catarrhalis. Epidemiol. Infect. 137(4), 581-590 (2009).
18. Cheepsattayakorn A, Tharavichitakul P, Dettrairat S, Sutachai V. Moraxella catarrhalis pneumonia in an AIDS patient: A case report. J. Med. Assoc. Thai. 92(2), 284-289 (2009).
19. Ioannidis JP, Worthington M, Griffiths JK, Snydman DR. Spectrum and significance of bacteremia due to Moraxella catarrhalis. Clin. Infect. Dis. 21(2), 390-397 (1995).
20. Bootsma HJ, Van Der Heide HG, Van De Pas S, Schouls LM, Mooi FR. Analysis of Moraxella catarrhalis by DNA typing: Evidence for a distinct subpopulation associated with virulence traits. J. Infect. Dis. 181(4), 1376-1387 (2000).
21. Mitov IG, Gergova RT, Ouzounova-Raykova VV. Distribution of genes encoding virulence factors ompB2, ompCD, ompE, beta-lactamase and serotype in pathogenic and colonizing strains of Moraxella catarrhalis. Arch. Med. Res. 41(7), 530-535 (2010).
22. Verhaegh SJ, Snippe ML, Levy F et al. Colonization of healthy children by Moraxella catarrhalis is characterized by genotype heterogeneity, virulence gene diversity and co-colonization with Haemophilus influenzae. Microbiology 157(Pt 1), 169-178 (2011).
23. Ahmed K, Matsumoto K, Rikitomi N, Nagatake T. Attachment of Moraxella catarrhalis to pharyngeal epithelial cells is mediated by a glycosphingolipid receptor. FEMS Microbiol. Lett. 135(2-3), 305-309 (1996).
24. Ahmed K, Nakagawa T, Nakano Y et al. Attachment of Moraxella catarrhalis occurs to the positively charged domains of pharyngeal epithelial cells. Microb. Pathog. 28(4), 203-209 (2000).
25. Rikitomi N, Ahmed K, Nagatake T. Moraxella (Branhamella) catarrhalis adherence to human bronchial and oropharyngeal cells: The role of adherence in lower respiratory tract infections. Microbiol. Immunol. 41(6), 487-494 (1997).
26. Balder R, Krunkosky TM, Nguyen CQ, Feezel L, Lafontaine ER. Hag mediates adherence of Moraxella catarrhalis to ciliated human airway cells. Infect. Immun. 77(10), 4597-4608 (2009).
27. Kukkonen M, Korhonen TK. The omptin family of enterobacterial surface proteases/ adhesins: From housekeeping in Escherichia coli to systemic spread of Yersinia pestis. Int. J. Med. Microbiol. 294(1), 7-14 (2004).
28. Lyskowski A, Leo JC, Goldman A. Structure and biology of trimeric autotransporter adhesins. Adv. Exp. Med. Biol. 715, 143-158 (2011).
29. Tan TT, Nordstrom T, Forsgren A, Riesbeck K. The respiratory pathogen Moraxella catarrhalis adheres to epithelial cells by interacting with fibronectin through ubiquitous surface proteins A1 and A2. J. Infect. Dis. 192(6), 1029-1038 (2005).
30. Hill DJ, Virji M. A novel cell-binding mechanism of Moraxella catarrhalis ubiquitous surface protein UspA: Specific targeting of the N-domain of carcinoembryonic antigen-related cell adhesion molecules by UspA1. Mol. Microbiol. 48(1), 117-129 (2003).
31. Brooks MJ, Sedillo JL, Wagner N et al. Moraxella catarrhalis binding to host cellular receptors is mediated by sequence-specific determinants not conserved among all UspA1 protein variants. Infect. Immun. 76(11), 5322-5329 (2008).
32. Conners R, Hill DJ, Borodina E et al. The Moraxella adhesin UspA1 binds to its human CEACAM1 receptor by a deformable trimeric coiled-coil. EMBO J. 27(12), 1779-1789 (2008).
33. Voges M, Bachmann V, Kammerer R, Gophna U, Hauck CR. CEACAM1 recognition by bacterial pathogens is species-specific. BMC Microbiol. 10, 117 (2010).
34. Agnew C, Borodina E, Zaccai NR et al. Correlation of in situ mechanosensitive responses of the Moraxella catarrhalis adhesin UspA1 with fibronectin and receptor CEACAM1 binding. Proc. Natl Acad. Sci. USA 108(37), 15174-15178 (2011).
35. Bullard B, Lipski SL, Lafontaine ER. Hag directly mediates the adherence of Moraxella catarrhalis to human middle ear cells. Infect. Immun. 73(8), 5127-5136 (2005).
36. Bullard B, Lipski S, Lafontaine ER. Regions important for the adhesin activity of Moraxella catarrhalis Hag. BMC Microbiol. 7, 65 (2007).
37. Holm MM, Vanlerberg SL, Foley IM, Sledjeski DD, Lafontaine ER. The Moraxella catarrhalis porin-like outer membrane protein CD is an adhesin for human lung cells. Infect. Immun. 72(4), 1906-1913 (2004).
38. Heiniger N, Troller R, Meier PS, Aebi C. Cold shock response of the UspA1 outer membrane adhesin of Moraxella catarrhalis. Infect. Immun. 73(12), 8247-8255 (2005).
39. Spaniol V, Troller R, Aebi C. Physiologic cold shock increases adherence of Moraxella catarrhalis to and secretion of interleukin 8 in human upper respiratory tract epithelial cells. J. Infect. Dis. 200(10), 1593-1601 (2009).
40. Slevogt H, Maqami L, Vardarowa K et al. Differential regulation of Moraxella catarrhalis-induced interleukin-8 response by protein kinase C isoforms. Eur. Respir. J. 31(4), 725-735 (2008).
41. Spaniol V, Troller R, Schaller A, Aebi C. Physiologic cold shock of Moraxella catarrhalis affects the expression of genes involved in the iron acquisition, serum resistance and immune evasion. BMC Microbiol. 11, 182 (2011).
42. Hoopman TC, Liu W, Joslin SN et al. Use of the chinchilla model for nasopharyngeal colonization to study gene expression by Moraxella catarrhalis. Infect. Immun. 80(3), 982-995 (2012).
43. Ye L WX, Jin M. Role of airway epithelial cells in development of chronic obstructive pulmonary disease. J. Epithelial Biol. Pharmacol. 2, 7 (2009).
44. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 359(22), 2355-2365 (2008).
45. Slevogt H, Schmeck B, Jonatat C et al. Moraxella catarrhalis induces inflammatory response of bronchial epithelial cells via MAPK and NF-kappaB activation and histone deacetylase activity reduction. Am. J. Physiol. Lung Cell Mol. Physiol. 290(5), L818-L826 (2006).
46. N'guessan PD, Temmesfeld-Wollbruck B, Zahlten J et al. Moraxella catarrhalis induces ERK- and NF-kappaB-dependent COX-2 and prostaglandin E2 in lung epithelium. Eur. Respir. J. 30(3), 443-451 (2007).
47. Schaar V, De Vries SP, Perez Vidakovics ML et al. Multicomponent Moraxella catarrhalis outer membrane vesicles induce an inflammatory response and are internalized by human epithelial cells. Cell. Microbiol. 13(3), 432-449 (2011).
48. Fink J, Mathaba LT, Stewart GA et al. Moraxella catarrhalis stimulates the release of proinflammatory cytokines and prostaglandin E from human respiratory epithelial cells and monocyte-derived macrophages. FEMS Immunol. Med. Microbiol. 46(2), 198-208 (2006).
49. Gompertz S, O'brien C, Bayley DL, Hill SL, Stockley RA. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur. Respir. J. 17(6), 1112-1119 (2001).
50. Parameswaran GI, Wrona CT, Murphy TF, Sethi S. Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. BMC Infect. Dis. 9, 178 (2009).
51. Vogelmeier C, Hubbard RC, Fells GA et al. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J. Clin. Invest. 87(2), 482-488 (1991).
52. Taggart CC, Lowe GJ, Greene CM et al. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J. Biol. Chem. 276(36), 33345-33352 (2001).
53. Sullivan AL, Dafforn T, Hiemstra PS, Stockley RA. Neutrophil elastase reduces secretion of secretory leukoproteinase inhibitor (SLPI) by lung epithelial cells: Role of charge of the proteinase-inhibitor complex. Respir. Res. 9, 60 (2008).
54. Manolov T, Tan TT, Forsgren A, Riesbeck K. Moraxella-dependent alpha 1-antichymotrypsin neutralization: A unique virulence mechanism. Am. J. Respir. Cell Mol. Biol. 38(5), 609-617 (2008).
55. Barnes PJ. Histone deacetylase-2 and airway disease. Ther. Adv. Respir. Dis. 3(5), 235-243 (2009).
56. Yang SR, Chida AS, Bauter MR et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am. J. Physiol. Lung Cell Mol. Physiol. 291(1), L46-57 (2006).
57. Adenuga D, Yao H, March TH, Seagrave J, Rahman I. Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am. J. Respir. Cell Mol. Biol. 40(4), 464-473 (2009).
58. Butler CA, McQuaid S, Taggart CC et al. Glucocorticoid receptor beta and histone deacetylase 1 and 2 expression in the airways of severe asthma. Thorax 67(5), 392-398 (2012).
59. N'guessan PD, Haarmann H, Steiner T, Suttorp N, Slevogt H. The Moraxella catarrhalis induced inflammatory response is mediated by activation of epidermal growth factor receptor in pulmonary epithelial cells. Am. J. Respir. Crit. Care Med. 179, A2831 (2009).
60. Tak PP, Firestein GS. NF-kappaB: A key role in inflammatory diseases. J. Clin. Invest. 107(1), 7-11 (2001).
61. Moscat J, Diaz-Meco MT, Rennert P. NF-kappaB activation by protein kinase C isoforms and B-cell function. EMBO Rep. 4(1), 31-36 (2003).
62. Kalinski P. Regulation of immune responses by prostaglandin E2. J. Immunol. 188(1), 21-28 (2012).
63. Lee HY, Andalibi A, Webster P et al. Antimicrobial activity of innate immune molecules against Streptococcus pneumoniae, Moraxella catarrhalis and nontypeable Haemophilus influenzae. BMC Infect. Dis. 4, 12 (2004).
64. Zhang W, Case S, Bowler RP, Martin RJ, Jiang D, Chu HW. Cigarette smoke modulates PGE(2) and host defence against Moraxella catarrhalis infection in human airway epithelial cells. Respirology 16(3), 508-516 (2011).
65. Soong G, Reddy B, Sokol S, Adamo R, Prince A. TLR2 is mobilized into an apical lipid raft receptor complex to signal infection in airway epithelial cells. J. Clin. Invest. 113(10), 1482-1489 (2004).
66. Slevogt H, Seybold J, Tiwari KN et al. Moraxella catarrhalis is internalized in respiratory epithelial cells by a trigger-like mechanism and initiates a TLR2- and partly NOD1-dependent inflammatory immune response. Cell. Microbiol. 9(3), 694-707 (2007).
67. Vuononvirta J, Toivonen L, Grondahl-Yli- Hannuksela K et al. Nasopharyngeal bacterial colonization and gene polymorphisms of mannose-binding lectin and Toll-like receptors 2 and 4 in infants. PLoS One 6(10), e26198 (2011).
68. Xie H, Gu XX. Moraxella catarrhalis lipooligosaccharide selectively upregulates ICAM-1 expression on human monocytes and stimulates adjacent naive monocytes to produce TNF-alpha through cellular cross-talk. Cell. Microbiol. 10(7), 1453-1467 (2008).
69. Clarke TB, Francella N, Huegel A, Weiser JN. Invasive bacterial pathogens exploit TLR-mediated downregulation of tight junction components to facilitate translocation across the epithelium. Cell Host Microbe 9(5), 404-414 (2011).
70. Spaniol V, Heiniger N, Troller R, Aebi C. Outer membrane protein UspA1 and lipooligosaccharide are involved in invasion of human epithelial cells by Moraxella catarrhalis. Microbes Infect. 10(1), 3-11 (2008).
71. Singh B, Su YC, Riesbeck K. Vitronectin in bacterial pathogenesis: A host protein used in complement escape and cellular invasion. Mol. Microbiol. 78(3), 545-560 (2010).
72. Jendholm J, Morgelin M, Perez Vidakovics ML et al. Superantigen- and TLR-dependent activation of tonsillar B cells after receptor-mediated endocytosis. J. Immunol. 182(8), 4713-4720 (2009).
73. Petterson T, Jendholm J, Mansson A, Bjartell A, Riesbeck K, Cardell LO. Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-like receptors. J. Leukoc. Biol. 89(2), 177-187 (2011).
74. Mogensen TH, Paludan SR, Kilian M, Ostergaard L. Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. J. Leukoc. Biol. 80(2), 267-277 (2006).
75. Gray-Owen SD, Blumberg RS. CEACAM1: Contact-dependent control of immunity. Nat. Rev. Immunol. 6(6), 433-446 (2006).
76. Chen Z, Chen L, Blumberg RS. Editorial: ceacam1: Fine-tuned for fine-tuning. J. Leukoc. Biol. 86(2), 195-197 (2009).
77. Bookwalter JE, Jurcisek JA, Gray-Owen SD, Fernandez S, McGillivary G, Bakaletz LO. A carcinoembryonic antigen-related cell adhesion molecule 1 homologue plays a pivotal role in nontypeable Haemophilus influenzae colonization of the chinchilla nasopharynx via the outer membrane protein P5-homologous adhesin. Infect. Immun. 76(1), 48-55 (2008).
78. Korotkova N, Yarova-Yarovaya Y, Tchesnokova V et al. Escherichia coli DraE adhesin-associated bacterial internalization by epithelial cells is promoted independently by decay-accelerating factor and carcinoembryonic antigen-related cell adhesion molecule binding and does not require the DraD invasin. Infect. Immun. 76(9), 3869-3880 (2008).
79. Sarantis H, Gray-Owen SD. Defining the roles of human carcinoembryonic antigen-related cellular adhesion molecules during neutrophil responses to Neisseria gonorrhoeae. Infect. Immun. 80(1), 345-358 (2012).
80. Lee HS, Ostrowski MA, Gray-Owen SD. CEACAM1 dynamics during Neisseria gonorrhoeae suppression of CD4+ T lymphocyte activation. J. Immunol. 180(10), 6827-6835 (2008).
81. Youssef AR, Van Der Flier M, Estevao S, Hartwig NG, Van Der Ley P, Virji M. Opa+ and Opa- isolates of Neisseria meningitidis and Neisseria gonorrhoeae induce sustained proliferative responses in human CD4+ T cells. Infect. Immun. 77(11), 5170-5180 (2009).
82. Slevogt H, Zabel S, Opitz B et al. CEACAM1 inhibits Toll-like receptor 2-triggered antibacterial responses of human pulmonary epithelial cells. Nat. Immunol. 9(11), 1270-1278 (2008).
83. Nagaishi T, Pao L, Lin SH et al. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity 25(5), 769-781 (2006).
84. N'guessan PD, Vigelahn M, Bachmann S et al. The UspA1 protein of Moraxella catarrhalis induces CEACAM-1-dependent apoptosis in alveolar epithelial cells. J. Infect. Dis. 195(11), 1651-1660 (2007).
85. Schmitter T, Agerer F, Peterson L, Munzner P, Hauck CR. Granulocyte CEACAM3 is a phagocytic receptor of the innate immune system that mediates recognition and elimination of human-specific pathogens. J. Exp. Med. 199(1), 35-46 (2004).
86. Schmitter T, Pils S, Weibel S et al. Opa proteins of pathogenic Neisseriae initiate Src kinase-dependent or lipid raft-mediated uptake via distinct human carcinoembryonic antigen-related cell adhesion molecule isoforms. Infect. Immun. 75(8), 4116-4126 (2007).
87. Pils S, Gerrard DT, Meyer A, Hauck CR. CEACAM3: An innate immune receptor directed against human-restricted bacterial pathogens. Int. J. Med. Microbiol. 298(7-8), 553-560 (2008).
88. Sarantis H, Gray-Owen SD. The specific innate immune receptor CEACAM3 triggers neutrophil bactericidal activities via a Syk kinase-dependent pathway. Cell. Microbiol. 9(9), 2167-2180 (2007).
89. Heiniger N, Spaniol V, Troller R, Vischer M, Aebi C. A reservoir of Moraxella catarrhalis in human pharyngeal lymphoid tissue. J. Infect. Dis. 196(7), 1080-1087 (2007).
90. Jendholm J, Samuelsson M, Cardell LO, Forsgren A, Riesbeck K. Moraxella catarrhalis-dependent tonsillar B cell activation does not lead to apoptosis but to vigorous proliferation resulting in nonspecific IgM production. J. Leukoc. Biol. 83(6), 1370-1378 (2008).
91. Gjorloff Wingren A, Hadzic R, Forsgren A, Riesbeck K. The novel IgD binding protein from Moraxella catarrhalis induces human B lymphocyte activation and Ig secretion in the presence of Th2 cytokines. J. Immunol. 168(11), 5582-5588 (2002).
92. Nordstrom T, Jendholm J, Samuelsson M, Forsgren A, Riesbeck K. The IgD-binding domain of the Moraxella IgD-binding protein MID (MID962-1200) activates human B cells in the presence of T cell cytokines. J. Leukoc. Biol. 79(2), 319-329 (2006).
93. Chen K, Xu W, Wilson M et al. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat. Immunol. 10(8), 889-898 (2009).
94. Vidakovics ML, Jendholm J, Morgelin M et al. B cell activation by outer membrane vesicles - A novel virulence mechanism. PLoS Pathog. 6(1), e1000724 (2010).
95. Krishnaswamy G, Martin R, Walker E et al. Moraxella catarrhalis induces mast cell activation and nuclear factor kappa B-dependent cytokine synthesis. Front. Biosci. 8, a40-a47 (2003).
96. Dew KF, Henry CJ, Mitchell LM, Hiltbolt EM, Swords We. H. influenzae and M. catarrhalis trigger a potemt immune response through activation of dendritic cells. J. Immunol. 182 (78.23) (2009).
97. Holt PG. Pulmonary dendritic cells in local immunity to inert and pathogenic antigens in the respiratory tract. Proc. Am. Thorac. Soc. 2(2), 116-120 (2005).
98. Amedei A, Della Bella C, Niccolai E et al. Moraxella catarrhalis-specific Th1 cells in BAL fluids of chronic obstructive pulmonary disease patients. Int. J. Immunopathol. Pharmacol. 22(4), 979-990 (2009).
99. Rosseau S, Wiechmann K, Moderer S et al. Moraxella catarrhalis-infected alveolar epithelium induced monocyte recruitment and oxidative burst. Am. J. Respir. Cell Mol. Biol. 32(2), 157-166 (2005).
100. Hoopman TC, Liu W, Joslin SN, Pybus C, Brautigam CA, Hansen EJ. Identification of gene products involved in the oxidative stress response of Moraxella catarrhalis. Infect. Immun. 79(2), 745-755 (2011).
101. Wang W, Kinkel T, Martens-Habbena W, Stahl DA, Fang FC, Hansen EJ. The Moraxella catarrhalis nitric oxide reductase is essential for nitric oxide detoxification. J. Bacteriol. 193(11), 2804-2813 (2011).
102. Avadhanula V, Rodriguez CA, Ulett GC, Bakaletz LO, Adderson EE. Nontypeable Haemophilus influenzae adheres to intercellular adhesion molecule 1 (ICAM-1) on respiratory epithelial cells and upregulates ICAM-1 expression. Infect. Immun. 74(2), 830-838 (2006).
103. Kocabas E, Sarikcioglu A, Aksaray N, Seydaoglu G, Seyhun Y, Yaman A. Role of procalcitonin, C-reactive protein, interleukin-6, interleukin-8 and tumor necrosis factor-alpha in the diagnosis of neonatal sepsis. Turk. J. Pediatr. 49(1), 7-20 (2007).
104. Kerfoot SM, Kubes P. Local coordination verses systemic disregulation: Complexities in leukocyte recruitment revealed by local and systemic activation of TLR4 in vivo. J. Leukoc. Biol. 77(6), 862-867 (2005).
105. Liu K, Casey J, Pichichero M. Serum intercellular adhesion molecule 1 variations in young children with acute otitis media. Clin. Vaccine Immunol. 17(12), 1909-1916 (2010).
106. Rosseau S, Hammerl P, Maus U et al. Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome. Am. J. Physiol. Lung Cell Mol. Physiol. 279(1), L25-35 (2000).
107. Lee JH, Del Sorbo L, Uhlig S et al. Intercellular adhesion molecule-1 mediates cellular cross-talk between parenchymal and immune cells after lipopolysaccharide neutralization. J. Immunol. 172(1), 608-616 (2004).
108. Park YS, Auo HJ, Jeon EJ, Chang KH, Lee SK, Lee DH. Effect of inhibitor of tumor necrosis factor-alpha and oxatomide on immune mediated otitis media. Laryngoscope 116(9), 1642-1646 (2006).
109. Blom AM, Hallstrom T, Riesbeck K. Complement evasion strategies of pathogens-acquisition of inhibitors and beyond. Mol. Immunol. 46(14), 2808-2817 (2009).
110. Hol C, Verduin CM, Van Dijke EE, Verhoef J, Fleer A, Van Dijk H. Complement resistance is a virulence factor of Branhamella (Moraxella) catarrhalis. FEMS Immunol. Med. Microbiol. 11(3), 207-211 (1995).
111. Hays JP, Ott A, Verduin CM, Van Belkum A, Kuipers S. Moraxella catarrhalis is only a weak activator of the mannose-binding lectin (MBL) pathway of complement activation. FEMS Microbiol. Lett. 249(2), 207-209 (2005).
112. Verduin CM, Kools-Sijmons M, Van Der Plas J et al. Complement-resistant Moraxella catarrhalis forms a genetically distinct lineage within the species. FEMS Microbiol. Lett. 184(1), 1-8 (2000).
113. Attia AS, Ram S, Rice PA, Hansen EJ. Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade. Infect. Immun. 74(3), 1597-1611 (2006).
114. Nordstrom T, Blom AM, Tan TT, Forsgren A, Riesbeck K. Ionic binding of C3 to the human pathogen Moraxella catarrhalis is a unique mechanism for combating innate immunity. J. Immunol. 175(6), 3628-3636 (2005).
115. Tan TT, Morgelin M, Forsgren A, Riesbeck K. Haemophilus influenzae survival during complement-mediated attacks is promoted by Moraxella catarrhalis outer membrane vesicles. J. Infect. Dis. 195(11), 1661-1670 (2007).
116. Hallstrom T, Nordstrom T, Tan TT et al. Immune evasion of Moraxella catarrhalis involves ubiquitous surface protein A-dependent C3d binding. J. Immunol. 186(5), 3120-3129 (2011).
117. Murphy TF, Brauer AL, Yuskiw N, Hiltke TJ. Antigenic structure of outer membrane protein E of Moraxella catarrhalis and construction and characterization of mutants. Infect. Immun. 68(11), 6250-6256 (2000).
118. Helminen ME, MacIver I, Latimer JL, Cope LD, McCracken GH Jr, Hansen EJ. A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model. Infect. Immun. 61(5), 2003-2010 (1993).
119. Peng D, Hu WG, Choudhury BP, Muszynski A, Carlson RW, Gu XX. Role of different moieties from the lipooligosaccharide molecule in biological activities of the Moraxella catarrhalis outer membrane. FEBS J. 274(20), 5350-5359 (2007).
120. Kiffer CR, Pignatari AC. Pharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens. BMC Infect. Dis. 11, 286 (2011).
121. Khan MA, Northwood JB, Levy F et al. bro {beta}-lactamase and antibiotic resistances in a global cross-sectional study of Moraxella catarrhalis from children and adults. J. Antimicrob. Chemother. 65(1), 91-97 (2010).
122. Jetter M, Spaniol V, Troller R, Aebi C. Down-regulation of porin M35 in Moraxella catarrhalis by aminopenicillins and environmental factors and its potential contribution to the mechanism of resistance to aminopenicillins. J. Antimicrob. Chemother. 65(10), 2089-2096 (2010).
123. Liu Y, Zhao C, Zhang F, Chen H, Chen M, Wang H. High prevalence and molecular analysis of macrolide-nonsusceptible Moraxella catarrhalis isolated from nasopharynx of healthy children in China. Microb. Drug Resist. doi:10.1089/ mdr.2011.0175 (2012) (Epub ahead of print).
124. Armbruster CE, Hong W, Pang B et al. Indirect pathogenicity of Haemophilus influenzae and Moraxella catarrhalis in polymicrobial otitis media occurs via interspecies quorum signaling. MBio 1(3), e00102-10 (2010).
125. Schaar V, Nordstrom T, Morgelin M, Riesbeck K. Moraxella catarrhalis outer membrane vesicles carry beta-lactamase and promote survival of Streptococcus pneumoniae and Haemophilus influenzae by inactivating amoxicillin. Antimicrob. Agents Chemother. 55(8), 3845-3853 (2011).
126. Pettigrew MM, Gent JF, Revai K, Patel JA, Chonmaitree T. Microbial interactions during upper respiratory tract infections. Emerg. Infect. Dis. 14(10), 1584-1591 (2008).
127. Lafontaine ER, Wall D, Vanlerberg SL, Donabedian H, Sledjeski DD. Moraxella catarrhalis coaggregates with Streptococcus pyogenes and modulates interactions of S. pyogenes with human epithelial cells. Infect. Immun. 72(11), 6689-6693 (2004).
128. Revai K, McCormick DP, Patel J, Grady JJ, Saeed K, Chonmaitree T. Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics 117(5), 1823-1829 (2006).
129. Dunne EM, Manning J, Russell FM, Robins-Browne RM, Mulholland EK, Satzke C. Effect of pneumococcal vaccination on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus in Fijian children. J. Clin. Microbiol. 50(3), 1034-1038 (2012).
130. Mawas F, Ho MM, Corbel MJ. Current progress with Moraxella catarrhalis antigens as vaccine candidates. Expert Rev. Vaccines 8(1), 77-90 (2009).
131. Yang M, Johnson A, Murphy TF. Characterization and evaluation of the Moraxella catarrhalis oligopeptide permease A as a mucosal vaccine antigen. Infect. Immun. 79(2), 846-857 (2011).
132. Easton DM, Cripps AW, Foxwell AR, Kyd JM. Mucosal immunization with the Moraxella catarrhalis porin M35 induces enhanced bacterial clearance from the lung: A possible role for opsonophagocytosis. Front. Microbiol. 13 (2), 1-11 (2011).
133. Luke-Marshall NR, Sauberan SL, Campagnari AA. Comparative analyses of the Moraxella catarrhalis type-IV pilus structural subunit PilA. Gene 477(1-2), 19-23 (2011).
134. Lugade AA, Bogner PN, Thanavala Y. Murine model of chronic respiratory inflammation. Adv. Exp. Med. Biol. 780, 125-141 (2011).
135. Cripps AW, Otczyk DC. Prospects for a vaccine against otitis media. Expert Rev. Vaccines 5(4), 517-534 (2006).
136. Sabirov A, Metzger DW. Mouse models for the study of mucosal vaccination against otitis media. Vaccine 26(12), 1501-1524 (2008).
137. Chen D, McMichael JC, Vandermeid KR et al. Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization. Infect. Immun. 64(6), 1900-1905 (1996).
138. Hu WG, Chen J, Battey JF, Gu XX. Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins. Infect. Immun. 68(9), 4980-4985 (2000).
139. Peng D, Hong W, Choudhury BP, Carlson RW, Gu XX. Moraxella catarrhalis bacterium without endotoxin, a potential vaccine candidate. Infect. Immun. 73(11), 7569-7577 (2005).
140. Liu DF, McMichael JC, Baker SM. Moraxella catarrhalis outer membrane protein CD elicits antibodies that inhibit CD binding to human mucin and enhance pulmonary clearance of M. catarrhalis in a mouse model. Infect. Immun. 75(6), 2818-2825 (2007).
141. Ren D, Xie H, Zhang W et al. Intranasal immunization of the combined lipooligosaccharide conjugates protects mice from the challenges with three serotypes of Moraxella catarrhalis. PLoS One 6(12), e29553 (2011).
142. Hirano T, Kodama S, Kawano T, Maeda K, Suzuki M. Monophosphoryl lipid A induced innate immune responses via TLR4 to enhance clearance of nontypeable Haemophilus influenzae and Moraxella catarrhalis from the nasopharynx in mice. FEMS Immunol. Med. Microbiol. 63(3), 407-417 (2011).
143. Hou Y, Hu WG, Hirano T, Gu XX. A new intra-NALT route elicits mucosal and systemic immunity against Moraxella catarrhalis in a mouse challenge model. Vaccine 20(17-18), 2375-2381 (2002).
144. Meier PS, Freiburghaus S, Martin A, Heiniger N, Troller R, Aebi C. Mucosal immune response to specific outer membrane proteins of Moraxella catarrhalis in young children. Pediatr. Infect. Dis. J. 22(3), 256-262 (2003).
145. Stutzmann Meier P, Heiniger N, Troller R, Aebi C. Salivary antibodies directed against outer membrane proteins of Moraxella catarrhalis in healthy adults. Infect. Immun. 71(12), 6793-6798 (2003).
146. Murphy TF, Brauer AL, Aebi C, Sethi S. Antigenic specificity of the mucosal antibody response to Moraxella catarrhalis in chronic obstructive pulmonary disease. Infect. Immun. 73(12), 8161-8166 (2005).
147. Bakri F, Brauer AL, Sethi S, Murphy TF. Systemic and mucosal antibody response to Moraxella catarrhalis after exacerbations of chronic obstructive pulmonary disease. J. Infect. Dis. 185(5), 632-640 (2002).
148. Adlowitz DG, Sethi S, Cullen P, Adler B, Murphy TF. Human antibody response to outer membrane protein G1a, a lipoprotein of Moraxella catarrhalis. Infect. Immun. 73(10), 6601-6607 (2005).
149. Adlowitz DG, Kirkham C, Sethi S, Murphy TF. Human serum and mucosal antibody responses to outer membrane protein G1b of Moraxella catarrhalis in chronic obstructive pulmonary disease. FEMS Immunol. Med. Microbiol. 46(1), 139-146 (2006).
150. Baumann U. Mucosal vaccination against bacterial respiratory infections. Expert Rev. Vaccines 7(8), 1257-1276 (2008).
151. Pavot V, Rochereau N, Genin C, Verrier B, Paul S. New insights in mucosal vaccine development. Vaccine 30(2), 142-154 (2012).
152. Kyd J, John A, Cripps A, Murphy TF. Investigation of mucosal immunisation in pulmonary clearance of Moraxella (Branhamella) catarrhalis. Vaccine 18(5-6), 398-406 (1999).
153. Gu XX, Chen J, Barenkamp SJ et al. Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis. Infect. Immun. 66(5), 1891-1897 (1998).
154. Jiao X, Hirano T, Hou Y, Gu XX. Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine. Infect. Immun. 70(11), 5982-5989 (2002).
155. Yu S, Gu XX. Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis. Infect. Immun. 73(5), 2790-2796 (2005).
156. Yu S, Gu XX. Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis. Infect. Immun. 75(6), 2974-2980 (2007).
157. Yu S, Xie H, Datta A, Naidu N, Gu XX. Galactose residues on the lipooligosaccharide of Moraxella catarrhalis 26404 form the epitope recognized by the bactericidal antiserum from conjugate vaccination. Infect. Immun. 76(9), 4251-4258 (2008).
158. Ren D, Yu S, Gao S et al. Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalis. Vaccine 29(25), 4210-4217 (2011).
159. Cox AD, St Michael F, Cairns CM et al. Investigating the potential of conserved inner core oligosaccharide regions of Moraxella catarrhalis lipopolysaccharide as vaccine antigens: Accessibility and functional activity of monoclonal antibodies and glycoconjugate derived sera. Glycoconj. J. 28(3-4), 165-182 (2011).
160. Pearson AG, Peak IR, Wilson JC, Grice ID. Synthesis of a novel pentasaccharide core component from the lipooligosaccharide of Moraxella catarrhalis. Carbohydr. Res. 346(17), 2805-2811 (2011).
161. Vidor E. The nature and consequences of intra- and inter-vaccine interference. J. Comp. Pathol. 137(Suppl. 1), S62-S66 (2007).
162. Mason KW, Zhu D, Scheuer CA, McMichael JC, Zlotnick GW, Green BA. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529. Vaccine 22(25-26), 3449-3456 (2004).
163. Mawas F, Ho MM, Huskisson R, Saydam M, Corbel MJ. Physico-chemical characterisation and immunogenicity of a multi-valent candidate vaccine against non-typeable Haemophilus influenzae and Moraxella catarrhalis. Vaccine 25(25), 4801-4808 (2007).
164. Hackett CJ, Harn DA. Vaccine Adjuvants: IMMUNOLOGICAL and Clinical Principles. Humana Press, Totowa, NJ, USA (2006).
165. Cluff CW, Baldridge JR, Stover AG et al. Synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect. Immun. 73(5), 3044-3052 (2005).
166. Saha S, Bhanja P, Liu L et al. TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome. PLoS One 7(1), e29357 (2012).
167. Baldridge JR, Cluff CW, Evans JT et al. Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): Induction of protective innate immune responses by RC-524 and RC-529. J. Endotoxin Res. 8(6), 453-458 (2002).
168. Judy BM, Taylor K, Deeraksa A et al. Prophylactic application of CpG oligonucleotides augments the early host response and confers protection in acute melioidosis. PLoS One 7(3), e34176 (2012).
169. Sabirov A, Metzger DW. Intranasal vaccination of neonatal mice with polysaccharide conjugate vaccine for protection against pneumococcal otitis media. Vaccine 24(27-28), 5584-5592 (2006).
170. Sun K, Johansen FE, Eckmann L, Metzger DW. An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage. J. Immunol. 173(7), 4576-4581 (2004).
171. Abe N, Kodama S, Hirano T, Eto M, Suzuki M. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. Laryngoscope 116(3), 407-412 (2006).
172. Kodama S, Abe N, Hirano T, Suzuki M. Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant. Laryngoscope 116(2), 331-335 (2006).
173. Patel GB, Zhou H, Ponce A, Harris G, Chen W. Intranasal immunization with an archaeal lipid mucosal vaccine adjuvant and delivery formulation protects against a respiratory pathogen challenge. PLoS One 5(12), e15574 (2010).
174. Pandey RS, Babbar AK, Kaul A, Mishra AK, Dixit VK. Evaluation of ISCOM matrices clearance from rabbit nasal cavity by gamma scintigraphy. Int. J. Pharm. 398(1-2), 231-236 (2010).
175. Kang ML, Cho CS, Yoo HS. Application of chitosan microspheres for nasal delivery of vaccines. Biotechnol. Adv. 27(6), 857-865 (2009).
176. Stano A, Van Der Vlies AJ, Martino MM, Swartz MA, Hubbell JA, Simeoni E. PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. Vaccine 29(4), 804-812 (2011).
177. Mangal S, Pawar D, Garg NK et al. Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally. Vaccine 29(31), 4953-4962 (2011).
178. Zaman M, Skwarczynski M, Malcolm JM et al. Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine. Nanomedicine 7(2), 168-173 (2011).
179. Chadwick S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv. Drug Deliv. Rev. 62(4-5), 394-407 (2010).
180. Bublin M, Hoflehner E, Wagner B et al. Use of a genetic cholera toxin B subunit/allergen fusion molecule as mucosal delivery system with immunosuppressive activity against Th2 immune responses. Vaccine 25(50), 8395-8404 (2007).
181. Jepson MA, Clark MA, Hirst BH. M cell targeting by lectins: A strategy for mucosal vaccination and drug delivery. Adv. Drug Deliv. Rev. 56(4), 511-525 (2004).
182. Mielcarek N, Debrie AS, Raze D et al. Attenuated Bordetella pertussis: New live vaccines for intranasal immunisation. Vaccine 24(Suppl. 2), S2-54-55 (2006).
183. Amuguni H, Lee S, Kerstein K et al. Sublingual immunization with an engineered Bacillus subtilis strain expressing tetanus toxin fragment C induces systemic and mucosal immune responses in piglets. Microbes Infect 14(5), 447-456 (2012).
184. Bhattacharya D, Mecsas J, Hu LT. Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis. Vaccine 28(48), 7683-7689 (2010).
185. Shi H, Wang S, Roland KL, Gunn BM, Curtiss R 3rd. Immunogenicity of a live recombinant Salmonella enterica serovar Typhimurium vaccine expressing pspA in neonates and infant mice born from naive and immunized mothers. Clin. Vaccine Immunol. 17(3), 363-371 (2010).
186. Garmory HS, Leary SE, Griffin KF, Williamson ED, Brown KA, Titball RW. The use of live attenuated bacteria as a delivery system for heterologous antigens. J. Drug Target. 11(8-10), 471-479 (2003).
187. Augustyniak D, Mleczko J, Gutowicz J. The immunogenicity of the liposome-associated outer membrane proteins (OMPs) of Moraxella catarrhalis. Cell Mol. Biol. Lett. 15(1), 70-89 (2010).
188. Pearson MM, Lafontaine ER, Wagner NJ, St Geme Jw, 3rd, Hansen EJ. A hag mutant of Moraxella catarrhalis strain O35E is deficient in hemagglutination, autoagglutination, and immunoglobulin D-binding activities. Infect. Immun. 70(8), 4523-4533 (2002).
189. Lipski SL, Akimana C, Timpe JM, Wooten RM, Lafontaine ER. The Moraxella catarrhalis autotransporter McaP is a conserved surface protein that mediates adherence to human epithelial cells through its N-terminal passenger domain. Infect. Immun. 75(1), 314-324 (2007).
190. Akimana C, Lafontaine ER. The Moraxella catarrhalis outer membrane protein CD contains two distinct domains specifying adherence to human lung cells. FEMS Microbiol. Lett. 271(1), 12-19 (2007).
191. Lafontaine ER, Cope LD, Aebi C, Latimer JL, McCracken GH Jr, Hansen EJ. The UspA1 protein and a second type of UspA2 protein mediate adherence of Moraxella catarrhalis to human epithelial cells in vitro. J. Bacteriol. 182(5), 1364-1373 (2000).
192. Timpe JM, Holm MM, Vanlerberg SL, Basrur V, Lafontaine ER. Identification of a Moraxella catarrhalis outer membrane protein exhibiting both adhesin and lipolytic activities. Infect. Immun. 71(8), 4341-4350 (2003).
193. Luke NR, Jurcisek JA, Bakaletz LO, Campagnari AA. Contribution of Moraxella catarrhalis type IV pili to nasopharyngeal colonization and biofilm formation. Infect. Immun. 75(12), 5559-5564 (2007).
194. Balder R, Hassel J, Lipski S, Lafontaine ER. Moraxella catarrhalis strain O35E expresses two filamentous hemagglutinin-like proteins that mediate adherence to human epithelial cells. Infect. Immun. 75(6), 2765-2775 (2007).
195. Qiu H, Kumita W, Sato K et al. uspA1 of Moraxella catarrhalis clinical isolates in Japan and its relationship with adherence to HEp-2 cells. J. Med. Dent. Sci. 56(1), 61-67 (2009).
196. Lipski SL, Holm MM, Lafontaine ER. Identification of a Moraxella catarrhalis gene that confers adherence to various human epithelial cell lines in vitro. FEMS Microbiol. Lett. 267(2), 207-213 (2007).
197. Plamondon P, Luke NR, Campagnari AA. Identification of a novel two-partner secretion locus in Moraxella catarrhalis. Infect. Immun. 75(6), 2929-2936 (2007).
198. Tan TT, Forsgren A, Riesbeck K. The respiratory pathogen Moraxella catarrhalis binds to laminin via ubiquitous surface proteins A1 and A2. J. Infect. Dis. 194(4), 493-497 (2006).
199. Singh B, Blom AM, Unal C, Nilson B, Morgelin M, Riesbeck K. Vitronectin binds to the head region of Moraxella catarrhalis ubiquitous surface protein A2 and confers complement-inhibitory activity. Mol. Microbiol. 75(6), 1426-1444 (2010).
200. Hu WG, Berry J, Chen J, Gu XX. Exploration of Moraxella catarrhalis outer membrane proteins, CD and UspA, as new carriers for lipooligosaccharide-based conjugates. FEMS Immunol. Med. Microbiol. 41(2), 109-115 (2004).
201. Murphy TF, Brauer AL, Aebi C, Sethi S. Identification of surface antigens of Moraxella catarrhalis as targets of human serum antibody responses in chronic obstructive pulmonary disease. Infect. Immun. 73(6), 3471-3478 (2005).
202. Tan TT, Christensen JJ, Dziegiel MH, Forsgren A, Riesbeck K. Comparison of the serological responses to Moraxella catarrhalis immunoglobulin D-binding outer membrane protein and the ubiquitous surface proteins A1 and A2. Infect. Immun. 74(11), 6377-6386 (2006).
203. Becker PD, Bertot GM, Souss D, Ebensen T, Guzman CA, Grinstein S. Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model. Infect. Immun. 75(4), 1778-1784 (2007).
204. Yang YP, Myers LE, McGuinness U et al. The major outer membrane protein, CD, extracted from Moraxella (Branhamella) catarrhalis is a potential vaccine antigen that induces bactericidal antibodies. FEMS Immunol. Med. Microbiol. 17(3), 187-199 (1997).
205. Murphy TF, Kirkham C, Liu DF, Sethi S. Human immune response to outer membrane protein CD of Moraxella catarrhalis in adults with chronic obstructive pulmonary disease. Infect. Immun. 71(3), 1288-1294 (2003).
206. Lafontaine ER, Snipes LE, Bullard B, Brauer AL, Sethi S, Murphy TF. Identification of domains of the Hag/MID surface protein recognized by systemic and mucosal antibodies in adults with chronic obstructive pulmonary disease following clearance of Moraxella catarrhalis. Clin. Vaccine Immunol. 16(5), 653-659 (2009).
207. Forsgren A, Brant M, Riesbeck K. Immunization with the truncated adhesin Moraxella catarrhalis immunoglobulin D-binding protein (MID764-913) is protective against M. catarrhalis in a mouse model of pulmonary clearance. J. Infect. Dis. 190(2), 352-355 (2004).
208. Verhaegh SJ, De Vogel CP, Riesbeck K et al. Temporal development of the humoral immune response to surface antigens of Moraxella catarrhalis in young infants. Vaccine 29(34), 5603-5610 (2011).
209. Easton DM, Smith A, Gallego SG, Foxwell AR, Cripps AW, Kyd JM. Characterization of a novel porin protein from Moraxella catarrhalis and identification of an immunodominant surface loop. J. Bacteriol. 187(18), 6528-6535 (2005).
210. Myers LE, Yang YP, Du RP et al. The transferrin binding protein B of Moraxella catarrhalis elicits bactericidal antibodies and is a potential vaccine antigen. Infect. Immun. 66(9), 4183-4192 (1998).
211. Chen D, McMichael JC, Vandermeid KR et al. Evaluation of a 74-kDa transferrin-binding protein from Moraxella (Branhamella) catarrhalis as a vaccine candidate. Vaccine 18(1-2), 109-118 (1999).
212. Aebi C, Cope LD, Latimer JL et al. Mapping of a protective epitope of the CopB outer membrane protein of Moraxella catarrhalis. Infect. Immun. 66(2), 540-548 (1998).
213. Mathers K, Leinonen M, Goldblatt D. Antibody response to outer membrane proteins of Moraxella catarrhalis in children with otitis media. Pediatr. Infect. Dis. J. 18(11), 982-988 (1999).
214. Liu DF, Xie X, Mastri MG et al. Polymorphism of the major surface epitope of the CopB outer membrane protein of Moraxella catarrhalis. FEMS Immunol. Med. Microbiol. 47(3), 343-350 (2006).
215. Murphy TF, Brauer AL, Yuskiw N, McNamara ER, Kirkham C. Conservation of outer membrane protein E among strains of Moraxella catarrhalis. Infect. Immun. 69(6), 3576-3580 (2001).
216. Ruckdeschel EA, Kirkham C, Lesse AJ, Hu Z, Murphy TF. Mining the Moraxella catarrhalis genome: Identification of potential vaccine antigens expressed during human infection. Infect. Immun. 76(4), 1599-1607 (2008).
217. Ruckdeschel EA, Brauer AL, Johnson A, Murphy TF. Characterization of proteins Msp22 and Msp75 as vaccine antigens of Moraxella catarrhalis. Vaccine 27(50), 7065-7072 (2009).
218. Hu WG, Chen J, McMichael JC, Gu XX. Functional characteristics of a protective monoclonal antibody against serotype A and C lipooligosaccharides from Moraxella catarrhalis. Infect. Immun. 69(3), 1358-1363 (2001).
219. Schwingel JM, Edwards KJ, Cox AD et al. Use of Moraxella catarrhalis lipooligosaccharide mutants to identify specific oligosaccharide epitopes recognized by human serum antibodies. Infect. Immun. 77(10), 4548-4558 (2009).
220. Gergova RT, Iankov ID, Haralambieva IH, Mitov IG. Bactericidal monoclonal antibody against Moraxella catarrhalis lipooligosaccharide cross-reacts with Haemophilus spp. Curr. Microbiol. 54(2), 85-90 (2007).